The approval of Fulphila was based on a comprehensive package of analytical, nonclinical and clinical data, which confirmed that the product is highly similar to Neulasta and no clinically meaningful differences in terms of safety and efficacy exist.
from India Infoline News Service https://ift.tt/2VAmZom
No comments:
Post a Comment